نتایج جستجو برای: Overall response rate (ORR)

تعداد نتایج: 2165667  

Journal: :Neuro-oncology 2022

Abstract Durable overall response rate (ORR) remains a meaningful endpoint in recurrent GBM; however, the target ORR for single arm GBM trials has not been based on historic information or tied to patient outcomes. The current study reviewed past order judiciously define ORRs use trials. After reviewing 69 treatment arms comprising 4,971 patients, was 6.1%[95% CI 4.23; 8.76%] cytotoxic chemothe...

The research study was designed to compare the safety and efficacy of the regimen of 5-flurouracil with cisplatin of investigational arm with the reference regimen of gemcitabine with cisplatin for the treatment of gallbladder cancer. A total of 60 patients were enrolled in the study. Out of 30 patients enrolled in arm-A (Gemcitabine with Cisplatin) and 30 patients enrolled in arm-B (5-Fluroura...

The research study was designed to compare the safety and efficacy of the regimen of 5-flurouracil with cisplatin of investigational arm with the reference regimen of gemcitabine with cisplatin for the treatment of gallbladder cancer. A total of 60 patients were enrolled in the study. Out of 30 patients enrolled in arm-A (Gemcitabine with Cisplatin) and 30 patients enrolled in arm-B (5-Fluroura...

2016
Makoto Nishio Toyoaki Hida Shinji Atagi Hiroshi Sakai Kazuhiko Nakagawa Toshiaki Takahashi Naoyuki Nogami Hideo Saka Mitsuhiro Takenoyama Makoto Maemondo Yuichiro Ohe Hiroshi Nokihara Tomonori Hirashima Hiroshi Tanaka Shiro Fujita Koji Takeda Koichi Goto Miyako Satouchi Hiroshi Isobe Koichi Minato Naoki Sumiyoshi Tomohide Tamura

OBJECTIVE Nivolumab is a fully human IgG4 programmed cell death 1 immune checkpoint inhibitor monoclonal antibody approved for the treatment of non-small cell lung cancer (NSCLC). The aim of this study was to evaluate the safety and efficacy of nivolumab in Japanese patients with advanced or recurrent non-squamous NSCLC. METHODS In this multicentre phase II study, patients with advanced or re...

B. Sun, J. Gao, J. He, J. Qiu, J. Yang, L. Qian, L. Yang, L. Zhou, R. Wang, Y. Huang, Y. Zhou, Y.Y. Cui, Y.Y. Zhang, Z.C. Tao,

Previous studies show inconsistent effect estimates for the efficacy of Endostar in patients with advanced non-small cell lung cancer (NSCLC) undergoing chemoradiotherapy. Therefore, this meta-analysis aimed to determine the effectiveness and safety on the basis of data obtained from available randomized controlled trials (RTCs). We find relevant articles reporting the use of Endostar combined ...

2017
Suresh K. Agarwal Naveen Mangal Rajeev M. Menon Kevin J. Freise Ahmed Hamed Salem

Background: Response rates such as overall response rate (ORR), complete response (CR) and complete response with incomplete blood recovery (CRi) can be evaluated in a much shorter period of time than overall survival (OS), potentially accelerating decision making during drug development. The objective of this work was to evaluate the relationship between ORR, CR, CRi or better (CRi+CR) rates a...

2015
Laurence Moureau-Zabotto Eric Teissier Didier Cowen David Azria Steve Ellis Michel Resbeut

The aim of the study is to analyze the impact of the Siewert classification on the pathological complete response (pcR), pattern of failure, and general outcome of patients treated, by preoperative chemoradiotherapy and surgery for an gastroesophageal junction adenocarcinoma (OGJA). From 2000 to 2008, the charts of 68 patients were retrospectively reviewed. Tumor staging reported was UST1/T2/T3...

2014
X.J. Wen L.M. Wang Z.L. Liu A. Huang Y.Y. Liu J.Y. Hu

We assessed the efficacy and tolerability of the augmentation of antidepressants (ATDs) with atypical antipsychotics (AAPs) to treat patients with major depressive disorder. A retrograde study to identify relevant patient data included databases of PubMed, EMBASE, Cochrane Central Register of Controlled Trials, and Database of Abstracts of Reviews of Effects. Data from 17 trials, involving 3807...

2007
Santosh Kumar Mondal Palash Kumar Mandal Shravasti Roy Pranab Kumar Biswas

While the combination of rituximab and polychemotherapy has improved prognosis of primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL, LT), advanced age of patients limits therapeutic options in relapsing/refractory cases. A multicenter single-arm phase II trial was conducted to assess benefit and safety of lenalidomide in refractory/relapsing PCDLBCL, LT. Primary endpoint was th...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید